View
224
Download
0
Category
Preview:
Citation preview
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
1/12
MODULE 8 ASSIGNMENT
TITLE/ TOPIC : PATIENT INFORMATION LEAFLET AND
LABEL OF RAMPRINAVIR
SUBMITTED BY : ADERSH.S.U.
BATCH : 20092011
REGISTRATION NO. : s044603
MENTOR NAME : Dr. LINCY JAISON
LEARNING GROUP NO. : 03
LOCATION : BANGALORE
DATE OF SUBMISSION : On BB Hard Copy
11/03/2011 07/03/2011
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
2/12
PART 1:
PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER
RAMPRINAVIR
CAPSULES FOR HIV INFECTIONS
Read this entire leaflet carefully before you starts using this medicine.
Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them,
even if their symptoms are the same as yours.
If any of the side effects gets serious, or if you notice any side effects not listed in thisleaflet, please tell your doctor or pharmacist.
In this leaflet:
1. What Ramprinaviris and what it is used for2. Before you take Ramprinavir3. How to take Ramprinavir4. Possible side effects5. How to store Ramprinavir6. Further information
1. What Ramprinavir is and what it is used for
Ramprinavir is used for the treatment of HIV (Human Immunodeficiency Virus)
infection.
Ramprinavir belongs to a group of medicines called viral neutralizers. The active
component of Ramprinavir is Zinovuprin. It is a HIV epitope, contains attenuated
pathogens. It elicits the immune system, especially B lymphocytes, the white blood cells,
to produce a type of antibodies called broadly neutralizing antibodies (bNAb). Broadly
neutralizing antibodies neutralizes almost all varieties of highly mutable HIV, block them
from infecting the target cells. The cell binding part of HIV is the target for bNAbs which
are relatively resistant to changes due to mutation.
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
3/12
Ramprinavir is used in combination with other medications, as a combination therapy.
You must keep taking all medicines prescribed by your doctor along with Ramprinavir,
for treating HIV infections as well as to treat all concomitant illness.
If youre pregnant, your doctor may want you to take Ramprinavir, to help prevent you
passing HIV on to your unborn baby. Ramprinavir may be given to your baby afterbirth,
to help prevent it from getting infected with HIV.
2. Before you take RamprinavirDont take Ramprinavir:
If you are allergic (hypersensitive) to Zenovuprin or any of the ingredients of
Ramprinavir
If you are with conditions such as anaemia (very low red blood cell count) or
neutropenia (very low white blood cell count)
Take special care with Ramprinavir:
Serious side effects are found in some people who are taking Ramprinavir. You need to
take care of the extra risks:
If you are either type I or type II diabetic and taking insulin
If you had experiences of any liver disorders
If you are obese (seriously overweight)
You need to talk to your doctor if any of these applies to you.
Ramprinavir and other medicines:
You must take special care if you are taking any other medicines while taking
Ramprinavir. Remember to inform your doctor or pharmacist if you start taking herbal
medicines or any other medicines you bought without prescription, while taking
Ramprinavir, as soon as possible.
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
4/12
Avoid these medicines with Ramprinavir:
Zalitabine, which is an anti-retroviral drug
Norfloxacin, which is an anti-microbial drug
Medicines that contribute many side effects or worsen the side effects when used
along wit Ramprinavir include:
Ureidopencillin, which is used for Klebsiella infections
Clotrimazole, used to treat fungal infections
Amodiaquine, used to treat malarial infections
Clofazine, which is an antileprotic drug
Topotecan, Etopolide or Lomustine, cytotoxic drugs used for the treatment ofcancer
Inform your doctor if you are taking any of these
Few medicines that interact with Ramprinavir:
Levodopa, used to treat Parkinsonism
Chloropromazine, which is an antiemetic
Inform your doctor if you are taking either Levodopa or Chloropromazine.
Pregnancy:
If you are pregnant or planning to become pregnant:
Ask about the benefits and risks of taking Ramprinavir, to your doctor.
Passing of HIV on to the unborn baby can be prevented by the regular use of Ramprinavir
during pregnancy.
Talk to your doctor about the possible side effects that can be caused by the Ramprinavir
to the unborn baby. Extra check-ups may be given to your baby to make sure it is
developing normally, if you have taken Ramprinavir, while you were pregnant
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
5/12
Breast feeding:
Women who are HIV positive must not breast feed, because HIV infection can be passed
on to the baby in breast milk.
Driving and using machines:
Ramprinavir can cause dizziness and other side effects that make you less alert. Avoid
driving or using machines if you are not feeling well.
Stay in contact with your doctor:
You need to stay in regular contact with your doctor, to stop your illness getting worse.
3. How to take Ramprinavir
Always take Ramprinavir exactly as your doctor has prescribed you to. Get back to your
doctor or pharmacist if you are not sure.
Swallow the capsules whole, with some water
Doses of Ramprinavir:
How much will you need to take:
Adults and adolescents with weight at least 30 kg:
The usual dose of Ramprinavir is 150mg thrice a day. Take each dose 8 hours apart.
Children weighing more than 21kg and less than 30kg:
A usual dose of 100mg Ramprinavir capsules twice a day.
Children weighing at least 14kg and less than or equal to 21kg:
The usual dose of Ramprinavir is one 100 mg capsule taken in the morning and two 100
mg capsules taken in the evening.
Children weighing at least 8kg and less than 14kg:
A usual dose of Ramprinavir is one 100mg capsules twice daily.
Ramprinavir capsules are not suitable for babies under 3 months old
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
6/12
Pregnancy, child birth and newborn babies:
You should not take Ramprinavir if you are at first 16 weeks of your pregnancy. You can
start taking a dose of 500mg Ramprinavir after the 16th
week until the delivery. Your new
born baby also may be given with Ramprinavir to help it prevent from getting infected
with HIV.
Ramprinavir overdosing:
If you take too much Ramprinavir:
If you take much Ramprinavir accidently, there is less likely the chances of developing
serious problems. Consumption of too much of Ramprinavir can cause symptoms such as
giddiness, tiredness, headache etc.
Dont stop taking Ramprinavir without proper advice.
4. Possible side effects
Ramprinavir can cause possible side effects to some, but not to everyone. Side effects
may observe in blood tests and may not appear until 4 to 5 weeks after you start taking
Ramprinavir. Your doctor may advise you to stop taking Ramprinavir if you get any of
these side effects.
Very common side effects:
Headache
Nausea
Theses may affect more than 1 in every 20 people taking Ramprinavir
Common side effects:
Vomiting
Diarrhoea
Stomach pain
Giddiness
These may affect up to 1 in every 20 people taking Ramprinavir
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
7/12
Uncommon side effects:
Suffocation
Fever
Skin rashes
Flatulence
These may affect up to 1 in every 100 people taking Ramprinavir
Rare side effects:
Chest pain
Loss of apatite
Jaundice
Insomnia
Feeling drowsy
Often urination
These may affect up to 1 in every 1000 people taking Ramprinavir
If any of these side effects gets worsen, inform your doctor or pharmacist as soon as
possible.
5. How to store Ramprinavir
Keep Ramprinavir away from direct sunlight
Do not store Ramprinavir above 350C
Store Ramprinavir in its original package
Keep Ramprinavir out of the reach of childrenDo not take Ramprinavir after the expiry date shown on the carton.
Do not try to dispose the unwanted Ramprinavir by yourself, hand it over to the
pharmacist.
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
8/12
6. Further information:
WhatRamprinavir contains:
The active substance is Zinovuprin
The other ingredients are:
Microcrystalline cellulose, magnesium stearate, sodium starch glycollate, gelatine,
opacode S-1-27831 black and titanium dioxide E281.
What Ramprinavir looks like and contents of the pack:
Ramprinavir capsules are marked A6N100. They are yellow, sealed with a dark-red
band, and supplied in bottles of 200 capsules.
Marketing Authorisation Holder and Manufacturer:
Marketing Authorisation Holder:
Nair Pharma UK, Boulevards, Bedford, London
Manufacturer:
Nair Pharma International, Colemore Row, Great Western Arcade, Birmingham
Other formats:
To request a copy of this leaflet in Braille or to listen to audio, please call, free of charge
0800 198 4926 (UK only)
Please be ready to give the following information:
Product name: Ramprinavir Capsules
Reference Number: 00012/1345
Leaflet date: March 2011
Ramprinavir is a registered trade mark of the Nair Pharma International group of
companies.
2011 Nair Pharma International group of companies
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
9/12
LABELLING
1. NAME OF THE MEDICINAL PRODUCT
Ramprinavir Capsules for HIV infection
2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each gram of Ramprinavir contains 50mg Zinovuprin
3. LIST OF EXCIPIENTS
Microcrystalline cellulose, magnesium stearate, sodium starch glycollate, gelatine,opacode S-1-27831 black and titanium dioxide E281
4. PHARMACEUTICAL FORM AND CONTENTS
Ramprinavir is a yellow coloured capsule sealed with a dark-red band, and supplied in
bottles of 200 capsules
5. METHOD(S) AND ROOTS OF ADMINISTRATION
Oral use
150mg thrice a day for adults
100mg twice a day for children
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BESTORED OUT OF THE REACH AND SIGHT OF CHILDREN
Keep Ramprinavir out of the reach and sight of children
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
10/12
7. OTHER SPECIAL WARNING(S), IF NECESSARY
Dont use if the seal is opened
Inform your doctor if you are taking either Levodopa or Chloropromazine, because it iscontraindicative with Ramprinavir
8. EXPIRY DATE
Exp. March 2014
9. SPECIAL STORAGE CONDITIONS
Store in room temperature (20270C)
Keep Ramprinavir away from direct sunlight
Do not refrigerate
10.SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED/UNWANTED MEDICINAL PRODUCTS
Do not try to dispose the unwanted Ramprinavir by yourself. Take it back to your
pharmacist, he will dispose it carefully
11.NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER
Nair Pharma UK, Boulevards, Bedford, London
Tel - +44 1723 2916
Fax- +44 1723 2917
12.MARKETING AUTHORISATION NUMBER(S)
EU/00012/1345
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
11/12
13.BATCH NUMBER
27356
14.GENERAL CLASSIFICATION FOR SUPPLY
Medicinal product subject to medical prescription
15.INSTRUCTIONS ON USE
Swallow the capsules whole, with some water
16.INFORMATION IN BRAINLLE
Ramprinavir Capsules for HIV infection
8/6/2019 PATIENT INFORMATION LEAFLET AND LABEL OF RAMPRINAVIR
12/12
PART 2:
CHANGES TO BE MADE TO MEET FDA REQUIREMENTS
The following changes should be made to the package insert (patient information leaflet), if the
drug has to be marketed in the United States
Detail description of the drug. It should include the details of the active substance(s) and
excipients, physical, chemical and molecular structure.
Warning and special consideration has to be made in the beginning.
Clinical pharmacology information of the drug including preclinical as well as clinical
evaluation data
Information regarding geriatric pharmacokinetic profile is required
Post marketing surveillance information, if available should be included in the packageinsert
Detail information regarding the adverse drug reactions
Patient counselling information is required
Manufacturing date must be included
Clinical trial information should be included in the label
Recommended